March 2025
·
2 Reads
Journal of the American Geriatrics Society
Background We aimed to examine the impact of sedative prescription patterns in hospitalized older adults on post‐discharge adverse drug events (ADEs), falls, and sleep. Methods We conducted a secondary analysis of the MedSafer randomized controlled trial (RCT; NCT03272607) which included hospitalized adults ≥ 65 years of age who were taking ≥ 5 medications. We identified patients who completed follow‐up at 30 days post‐discharge and provided patient‐reported outcomes for sleep disturbance (PROMIS SD 4a). We grouped patients based on sedative use as follows: nonusers, continued home use (pre‐ and post‐hospitalization), deprescribed home use, and new use at discharge. Using multivariable logistic regression, we compared the odds of patients having experienced ≥ 1 ADE (not necessarily ascribed to sedatives), a fall, or any adverse event within 30 days post‐discharge. We also used ordinal logistic regression and a minimal important difference approach to compare the change in sleep disturbance at 30 days post‐discharge. Results The cohort comprised 3630 patients with a median age of 78. A total of 2810 (77.4%) were categorized as nonusers; 475 (13.1%) continued home use; 293 (8.1%) deprescribed home use; and 52 (1.4%) new users at discharge. Compared to the continued home use group, the deprescribed group was substantially less likely to experience an ADE post‐discharge (adjusted odds ratio [aOR], 0.39 [95% CI, 0.16–0.97]). Correspondingly, new users at discharge had substantially higher odds of falls (aOR, 2.51 [95% CI, 1.13–5.61]). Favorable changes in sleep disturbance were more likely among nonusers (aOR, 1.29 [95% CI, 1.05–1.58]) and deprescribed users (aOR, 1.11 [95% CI, 0.82–1.50]) when compared to continued users. Conclusions In this cohort, patients who had their sedatives deprescribed were 61% less likely than continued users to have a post‐discharge ADE, and new sedative use at discharge was associated with appreciable risk of falls. Hospitalization likely represents a window of opportunity to improve care by promoting sedative deprescription and avoiding new starts.